Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?

SE Engelen, AJB Robinson, YX Zurke… - Nature Reviews …, 2022 - nature.com
Atherosclerosis is a chronic inflammatory disease of the arterial wall, characterized by the
formation of plaques containing lipid, connective tissue and immune cells in the intima of …

Targeting inflammation in atherosclerosis—from experimental insights to the clinic

O Soehnlein, P Libby - Nature reviews Drug discovery, 2021 - nature.com
Atherosclerosis, a dominant and growing cause of death and disability worldwide, involves
inflammation from its inception to the emergence of complications. Targeting inflammatory …

Mendelian randomization: concepts and scope

RC Richmond, GD Smith - Cold Spring …, 2022 - perspectivesinmedicine.cshlp.org
Mendelian randomization (MR) is a method of studying the causal effects of modifiable
exposures (ie, potential risk factors) on health, social, and economic outcomes using genetic …

Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease

PM Ridker, M Rane - Circulation research, 2021 - Am Heart Assoc
IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of
physiological functions traditionally associated with host defense, immune cell regulation …

IL-6 in inflammation, autoimmunity and cancer

T Hirano - International immunology, 2021 - academic.oup.com
IL-6 is involved both in immune responses and in inflammation, hematopoiesis, bone
metabolism and embryonic development. IL-6 plays roles in chronic inflammation (closely …

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

PM Ridker, M Devalaraja, FMM Baeres… - The Lancet, 2021 - thelancet.com
Background IL-6 has emerged as a pivotal factor in atherothrombosis. Yet, the safety and
efficacy of IL-6 inhibition among individuals at high atherosclerotic risk but without a …

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

G Guaraldi, M Meschiari, A Cozzi-Lepri… - The Lancet …, 2020 - thelancet.com
Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial

EC Svensson, A Madar, CD Campbell, Y He… - JAMA …, 2022 - jamanetwork.com
Importance Clonal hematopoiesis of indeterminate potential (CHIP) is associated with
increased risk of atherosclerotic cardiovascular disease, and mouse experiments suggest …

Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms

S Kang, T Kishimoto - Experimental & molecular medicine, 2021 - nature.com
Abstract Interleukin-6 (IL-6) plays a crucial role in host defense against infection and tissue
injuries and is a bioindicator of multiple distinct types of cytokine storms. In this review, we …

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

TJ Guzik, SA Mohiddin, A Dimarco, V Patel… - Cardiovascular …, 2020 - academic.oup.com
The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents
the greatest medical challenge in decades. We provide a comprehensive review of the …